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VOLUME 56 2012 NUMBER 4
Issues In The Third Circuit
PRESCRIPTION FOR CHANGE: THIRD CIRCUIT DIAGNOSES
PHARMACEUTICAL SALES REPRESENTATIVES AS
EXEMPT FROM OVERTIME PAY IN SMITH v.
JOHNSON & JOHNSON
BROOKE BuRNs*
"[A] title alone is of little or no assistance in determining the true im-
portance of an employee to the employer. Titles can be had cheaply
and are of no determinative value." - Harold Stein'
* Villanova University School of Law, J.D. Candidate 2012; Boston College,
B.A. 2006. The author would like to thank Professor Bryant D. Lim for his
guidance in writing this Casebrief. The author would also like to acknowledge
Amy M. Dudash for her feedback and assistance throughout the process. This
Casebrief would not have been possible without the support of her family and
Joseph J. Mahady.
1. WAGE AND HOUR Div., U.S. DEP'T OF LABOR, PUB. No. 1412, "EXECUTIVE,
ADMINISTRATIVE, PROFESSIONAL . . . OUTSIDE SALESMAN" REDEFINED: REPORT AND
RECOMMENDATIONS OF THE PRESIDING OFFICER AT HEARINGS PRELIMINARY TO REDEFI-
NITION 25 (1940) [hereinafter STEIN REPORT] (recognizing superficiality ofjob ti-
tles and arguing that an employee's job title, therefore, is not dispositive to
determine exemption status under Fair Labor Standards Act (FLSA)); see also
Evancho v. Sanofi-Aventis U.S. Inc., No. 07-2266, 2007 WL 4546100, at *3 (D.N.J.
Dec. 19, 2007) (declining to reach merits of exemption arguments but recognizing
potential for plaintiffs and potential collective action members to have varied du-
ties and responsibilities despite possessing same job title of pharmaceutical sales
representative (PSR)); Aguirre v. SBC Commc'ns, Inc., No. 05-3198, 2006 WL
964554, at *7 (S.D. Tex. Apr. 11, 2006) (explaining that employees' status under
FLSA may vary, even if they have same job title, if their job responsibilities and
duties differ among each other). But see IMS Health Inc. v. Ayotte, 550 F.3d 42, 46-
47 (1st Cir. 2008) (discussing general function of PSRs across industry), abrogated
by Sorrell v. IMS Health Inc., 131 S. Ct. 2653 (2011); Schaefer-LaRose v. Eli Lilly &
Co., 663 F. Supp. 2d 674, 694 n.14 (S.D. Ind. 2009) (summarizing cases addressing
issue of PSR exemption status that have same or similar facts); Baum v. As-
traZeneca LP, 605 F. Supp. 2d 669, 687 (W.D. Pa. 2009) (discussing role of PSRs),
affd, 372 F. App'x 246 (3d Cir. 2010), cert. denied, 131 S. Ct. 332 (2010).
(671)
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I. PATIENT PRESENTS WITH CONFLICTING SYMPTOMS
Pharmaceutical companies that manufacture brand-name drugs, how-
ever, would respectfully disagree with Harold Stein because the title of
pharmaceutical sales representative (PSR) comes with a multi-billion dol-
lar price tag and provides a multi-hundred-billion dollar return on invest-
ment.2 Prepared by an intensive sales training program and readied with
an armamentarium of company-approved sales materials and "core
messages," the well-groomed PSR sitting in the waiting room is more than
just a pretty face.3 Often serving as the only direct link between physicians
2. See IMS Health Inc. v. Mills, 616 F.3d 7, 14 (1st Cir. 2010) (describing de-
tailing as "a massive and expensive undertaking for pharmaceutical manufacturers,
which spend billions of dollars a year to have some 90,000 pharmaceutical sales
representatives make weekly or monthly one-on-one visits to prescribers nation-
wide" (citing Stephanie Saul, Doctors Object to Gathering of Drug Data, N.Y. TIMES,
May 4, 2006, at Al)); Joseph Barfett et al., Pharmaceutical Marketing to Medical Stu-
dents: The Student Perspective, 8 McGILLJ. MED. 21, 21-27 (2004), available at http://
www.medicine.mcgill.ca/MJM/issues/v08nO1/origarticles/barfett.pdf (asserting
that pharmaceutical industry in 2002 spent twenty-five percent of promotional ex-
penditures that totaled $21 billion (over $5 billion) on detailing pharmaceutical
products to physicians); Ashley Wazana, Physicians and the Pharmaceutical Industry: Is
a Gift Ever just a Gift?, 283 J. AM. MED. Ass'N 373, 373 (2000), available at http://
jama.ama-assn.org/content/283/3/373.full.pdf+html (estimating that, of $5 bil-
lion spent on PSRs in 2000, "$8000 to $13000 [was] spent per year on each physi-
cian"). But see Ayotte, 550 F.3d at 56 (stating that "[t]he fact that the
pharmaceutical industry spends over $4,000,000,000 annually on detailing bears
loud witness to its efficacy"); U.S. CENSUS BuREAu, STATISTICAL ABSTRACT OF THE
UNITED STATES: 2012, at 113 tbl.159 (131st ed. 2011), available at http://www.cen-
sus.gov/compendia/statab/201 1/tables/1 IsOl 55.pdf (setting forth table, "Retail
Prescription Drug Sales: 1995 to 2009," illustrating increase in retail prescription
drug sales); Puneet Manchanda & Elisabeth Honka, The Effects and Role of Direct-to-
Physician Marketing in the Pharmaceutical Industry: An Integrative Review, 5 YALE J.
HEALTH POL'Y L. & ETHICs 785, 804 (2005) (noting studies that show "detailing has
a positive and significant effect on sales" and that "the effect of detailing is largest
relative to other marketing instruments").
3. See, e.g., Smith v. Johnson & Johnson, 593 F.3d 280, 282 (3d Cir. 2010)
(discussing how pharmaceutical company provided PSR with target list of physi-
cians to see, prepared messages to deliver, and "pre-approved" sales aid to use);
Amendola v. Bristol-Myers Squibb Co., 558 F. Supp. 2d 459, 464 (S.D.N.Y. 2008)
(identifying that pharmaceutical company "developed a 'core message' about each
drug and train [ed] P[S]Rs to relay that message on every visit"); Cote v. Burroughs
Wellcome Co., 558 F. Supp. 883, 885 (E.D. Pa. 1982) (stating that pharmaceutical
company provided detailers "with an extensive set of selling tools"). Although
PSRs may appear as robotic "Stepford Wives," they are highly trained and edu-
cated. See Stephanie Saul, Gimme an Rx! Cheerleaders Pep Up Drug Sales, N.Y. TIMES,
Nov. 28, 2005, at Al, available at http://www.nytimes.com/2005/11/28/business/
28cheer.html?pagewanted=all ("Anyone who has seen the parade of sales repre-
sentatives through a doctor's waiting room has probably noticed that they are fre-
quently female and invariably good looking."). But see Susan Heilbronner Fisher,
Note, The Economic Wisdom of Regulating Pharmaceutical "Freebies", 1991 DuKE L.J.
206, 227 (maintaining that PSRs experience "rigorous scientific training" and that
pharmaceutical companies "spend[ ] large sums of money to train each detailer to
be a combination of a scientist, a business strategist, and a communicator"); Joshua
Weiss, Note, Medical Marketing in the United States: A Prescription for Reform, 79 GEO.
WASH. L. REv. 260, 264 (2010) (explaining that PSRs "receive extensive-albeit
[Vol. 56: p. 671672
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and the pharmaceutical companies, PSRs are responsible for "detailing"
prescription products through targeted messages to physicians.4 PSRs,
therefore, typically have a heavy hand in influencing which prescription a
patient ultimately fills at the pharmacy.5
Contrary to popular perception, PSRs do not sell pharmaceutical
drugs directly to physicians.6 Instead, pharmaceutical companies provide
PSRs with incentive compensation based on their ability to induce physi-
cians to prescribe their respective products to patients, resulting in a final
consummated sale at the pharmacy level.7 PSRs, therefore, do not com-
port with traditional notions of the American door-to-door salesman or
nonmedical-training to hone their craft"); Shena T. Wheeler, Note, Under the
Influence: An Examination of the Tactics Pharmaceutical Companies Use to Manipulate
Physicians, 7 IND. HEALTH L. REV. 89, 94 (2010) (stating that PSRs are "experts
regarding the drugs they sell").
4. SeeME. REv. STAT. tit. 22, § 1711-E(l) (A-2) (defining "detailing" as "one-to-
one contact with a prescriber or employees or agents of a prescriber for the pur-
pose of increasing or reinforcing the prescribing of a certain drug by the pre-
scriber"); Ayotte, 550 F.3d at 46 (explaining "tailored" nature of detailing); Bernard
J. Garbutt III & Melinda E. Hofmann, Recent Developments in Pharmaceutical Products
Liability Law: Failure to Warn, the Learned Intermediary Defense, and Other Issues in the
New Millennium, 58 FooD & DRUG L.J. 269, 271 (2003) (discussing PSRs as provid-
ing important link between physicians and pharmaceutical companies).
5. See Ayotte, 550 F.3d at 56 ("Detailing works: that it succeeds in inducing
physicians to prescribe larger quantities of brand-name drugs seems clear (even if
the exact magnitude of that effect is not)." (citations omitted)); In re Novartis
Wage & Hour Litig., 593 F. Supp. 2d 637, 648-51 (S.D.N.Y. 2009) (emphasizing
role of PSRs in purchase cycle of prescription drugs), vacated, 611 F.3d 141 (2d Cir.
2010), cert. denied, 131 S. Ct. 1568 (2011); Ruggeri v. Boehringer Ingelheim
Pharm., Inc., 585 F. Supp. 2d 254, 257-60 (D. Conn. 2008) (reasoning that "as
result of promotional efforts of PSRs, the physicians whom they solicited may have
written prescriptions that caused their patients to purchase drugs manufactured by
pharmaceutical company that employed them"); GRAHAM DUKES, THE LAW AND
ETHICS OF THE PHARMACEUTICAL INDUSTRY 202 (2006) ("It is recognized in the
pharmaceutical industry that the traveling representative (medical visitor,
detailman) is for the industry the most effective form of persuasion which it pos-
sesses."); David Orentlicher, Prescription Data Mining and the Protection of Patients'
Interests, 38J.L. MED. & ETHICS 74, 76 (2010) (discussing detailing as more persua-
sive than advertisements).
6. See 21 U.S.C. §§ 351-60 (2006) (detailing extensive restrictions regarding
pharmaceutical products under federal Food, Drug, and Cosmetic Act (FDCA)).
Because of the highly regulated nature of the pharmaceutical industry, PSRs can-
not legally sell pharmaceutical products directly to physicians. See 21 U.S.C.
§ 353(b) (1) (prohibiting pharmaceutical companies and PSRs from transferring
title to prescription products directly to doctors or patients); see also Novartis, 593 F.
Supp. 2d at 642 (explaining that PSRs persuade "physicians to write prescriptions
that are ultimately used by patients" by obtaining "non-binding commitments"
from physicians).
7. See Kuzinski v. Schering Corp., 604 F. Supp. 2d 385, 396-97 (D. Conn. 2009)
(describing manner in which PSRs receive incentive compensation to receive
"credit" for "sale" of prescription drugs to physicians), aff'd, 384 F. App'x 17 (2d
Cir. 2010), cert. denied, 131 S. Ct. 1567 (2011); Novartis, 593 F. Supp. 2d at 653
(reasoning that PSRs obtain commitments to prescribe and "are credited with
those sales and compensated accordingly by means of incentive payments").
3
Burns: Prescription for Change: Third Circuit Diagnoses Pharmaceutical S
Published by Villanova University Charles Widger School of Law Digital Repository, 2012
VILLANOVA LAW REVIEW
the archetypal business consultant.8 As a result, courts are struggling to
address whether PSRs are exempt from overtime pay under the Fair Labor
Standards Act (FLSA).'
8. See Steven R. Blackburn, In re Novartis Wage and Hour Litigation, in Top 20
FOOD AND DRUG CASES, 2009 & CASES TO WATCH, 2010, at 159, 164 (John B. Reiss
ed., 2010), available at http://www.ebglaw.com/files/39680_FDLI s%20Top%20
20%2OFood%20and%2oDrug%2OCases%20-%2OChap%20%2012%20Blackbum
%20 (Douglas%20Weiner).PDF (differentiating PSRs from "old-fashioned, door-to-
door salesmen"); Lars Noah, Death of a Salesman: To What Extent Can the JDA Regu-
late the Promotional Statements of Pharmaceutical Sales Representatives?, 47 FOOD & DRUG
L.J. 309, 331 (1992) (discussing how "[d]etailing is not advertising in the tradi-
tional sense").
9. See, e.g., Christopher v. SmithKline Beecham Corp., 635 F.3d 383, 401 (9th
Cir.) (finding PSRs "share many more similarities than differences with their col-
leagues in other sales fields, and we hold that they are exempt from the FLSA
overtime-pay requirement"), cert. granted, No. 11-204, 2011 WL 3608968 (U.S.
2011); Schaefer-LaRose v. Eli Lilly & Co., 663 F. Supp. 2d 674, 686 (S.D. Ind. 2009)
(determining that PSR was "acting as a sales agent" because she "sought and re-
ceived commitments, albeit nonbinding commitments, from physicians" to pre-
scribe pharmaceutical company's drugs); Harris v. Auxilium Pharm., Inc., 664 F.
Supp. 2d 711, 742 (S.D. Tex. 2009) (concluding that medical sales consultants
(PSRs) function as outside salespersons because they "make 'sales' by securing a
physician's commitment to write a prescription"), vacated in part, No. 4:07-cv-3938,
2010 WL 3817150 (S.D. Tex. Sept. 28, 2010); Yacoubian v. Ortho-McNeil Pharm.,
Inc., No. SACV 07-00127-CJC(MLGx), 2009 WL 3326632, at *6 (C.D. Cal. Feb. 6,
2009) (asserting that PSRs are outside salespersons because they "are precisely the
type of employees envisioned when Congress established the outside salesman ex-
emption from the FLSA"); Delgado v. Ortho-McNeil, Inc., No. SACV 07-00263-
CJC(MLGx), 2009 WL 2781525, at *6 (C.D. Cal. Feb. 6, 2009) (stating that duties
and responsibilities of PSRs could not be attributed to anything besides selling);
Novartis, 593 F. Supp. 2d at 637, 648 (reasoning that failing to interpret PSRs as
outside salespersons would ignore FLSA's "spirit, purpose, and goals"); Rivera v.
Schering Corp., No. 08-1743-gw(JCx), 2008 WL 6953955, at *3 n.3 (C.D. Cal. Aug.
14, 2008) (finding that PSRs "obtain [ ] orders" and, therefore, satisfy OSEE);
Brody v. AstraZeneca Pharm., LP, No. CV 06-6862 ABC (MANx), 2008 WL
6953957, at *8 (C.D. Cal. June 11, 2008) (arguing that PSR indirectly consum-
mated sales but that it did not detract from "sales quality of [PSR]'s work"); Menes
v. Roche Labs., Inc., No. 2:07-cv-01444-ER-FFMx, 2008 WL 6600518, at *1-2 (C.D.
Cal. Jan. 7, 2008) (holding that PSRs were outside salespersons even though they
did not sell prescription "products to medical personnel in the classic sense");
Barnick v. Wyeth, 522 F. Supp. 2d 1257, 1264 (C.D. Cal. 2007) (refusing to ignore
logic that PSRs' sales "efforts are rationally aimed at those determining the prod-
uct's purchase rather than the directed buyers of the product"); D'Este v. Bayer
Corp., No. CV 07-3206-JFW (PLAx), 2007 WL 6913682, at *4 (C.D. Cal. Oct. 9,
2007) (interpreting physician as "buyer" who "place[s] an order" with PSR). But
see Novartis, 611 F.3d at 153 (reversing district court's decision and finding that
PSRs merely promote products that are sold by another person); Jirak v. Abbott
Labs., Inc., 716 F. Supp. 2d 740, 748 (N.D. Ill. 2010) (acknowledging that PSRs
"bear some indicia of salesmen" but ultimately finding that reps promoted but did
not make sales); Ruggei, 585 F. Supp. 2d at 272, 272 n.10 (recognizing "gap be-
tween a PSR's marketing pitch and the ultimate transfer of the drugs to an individ-
ual patient-consumer" and refusing to "back-fit the FLSA to the practices of the
industry"); Amendola v. Bristol-Myers Squibb Co., 558 F. Supp. 2d 459, 471
(S.D.N.Y. 2008) (concluding that PSR's duties consisted of promotional work,
which did not constitute making sales).
674 [Vol. 56: p. 671
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Prompted by President Roosevelt's New Deal efforts, Congress en-
acted the FLSA in 1938 to rejuvenate the economy and provide a better
standard of living for American workers.10 Seeking to "promote economic
justice and security for the lowest paid of [American] wage earners," Con-
gress enacted minimum wage and maximum hour protections, including
the requirement to pay employees overtime for working in excess of forty
hours per week." These early constraints on employers have evolved to
become "among the nation's most important worker protections" today.' 2
Congress, however, identified that gradations in employment existed be-
tween workers and, therefore, precluded "any employee employed in a
bona fide executive, administrative, professional, or local retailing capac-
ity, or in the capacity of outside salesmen" from enjoying these
protections. 13
10. See Fair Labor Standards Act of 1938 (FLSA), 29 U.S.C. §§ 201-19 (2006)
(establishing congressional finding and declaration of policy to correct and elimi-
nate poor working conditions); Roland Elec. Co. v. Walling, 326 U.S. 657, 669-70
(1946) (discussing FLSA's enactment in 1938 as part of New Deal to protect work-
ers from "substandard labor conditions"), superseded by statute, 29 U.S.C. § 202; 81
CONG. REc. 4983 (1937) (sending initial version of bill to Congress with message
that America should give workers "a fair day's pay for a fair day's work"); Deborah
C. Malamud, Engineering the Middle Classes: Class Line-Drawing in New Deal Hours
Legislation, 96 MICH. L. REv. 2212, 2289 (1998) (explaining that FLSA worker pro-
tections stemmed from Roosevelt administration's "strengthened ... resolve that
there was to be no collar-color distinction in the wage and hour laws").
11. S. REP. No. 81-640 (1949), rqpinted in 1949 U.S.S.C.A.N. 2241, 2255; see 29
U.S.C. §§ 206, 207 (detailing minimum wage and maximum hour protections);
Barrentine v. Ark.-Best Freight Sys., Inc., 450 U.S. 728, 739 (1981) ("The FLSA was
designed to give specific minimum protections to individual workers and to ensure
that each employee . . . would be protected from the evil of overwork as well as
underpay." (internal quotations omitted)).
12. Defining and Delimiting the Exemptions for Executive, Administrative,
Professional, Outside Sales and Computer Employees, 69 Fed. Reg. 22,122, 22,122
(Apr. 23, 2004) (discussing FLSA as preeminent tool for enforcing and protecting
employees' rights and wages). The current FLSA protections provide for mini-
mum wages and overtime pay, requiring payment of time-and-a-half for every hour
worked over forty hours per week. See 29 U.S.C. §§ 206, 207 (detailing minimum
wage and maximum hour requirements); see alsojoseph E. Tilson et al., Hot Topics
in Wage and Hour Law, in 38TH ANNUAL INSTITUTE ON EMPLOYMENT LAw 681, 685
(PLI Litig. & Admin. Practice, Course Handbook Ser. No. 802, 2009) ("Through
2008, the FLSA remains the most lucrative statute for the Department of Labor's
Wage and Hour Division, which recovered $140.2 million in minimum wage and
overtime payments on behalf of more than 197,000 employees."); Wages, U.S.
DEP'T OF LABOR, http://www.dol.gov/dol/topic/wages/index.htm (stating mini-
mum wage is $7.25 per hour as ofJune 24, 2009).
13. See 29 U.S.C. § 213 (detailing five exemptions to FLSA); see MARC LINDER,
"TIME AND A HALF'S THE AMERICAN WAY": A HISTORY OF THE EXCLUSION OF WHITE-
COLLAR WORKERS FROM OVERTIME REGULATION, 1868-2004, at 513-21, 678 (2004)
(discussing necessity of worker protections but clarifying that they were not in-
tended for all); Malamud, supra note 10, at 2223-24 (explaining that white-collar
workers were previously unprotected because "pre-New Deal hours legislation was
health-oriented, and the working conditions of white-collar workers were not as
injurious to health as those of industrial workers").
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Courts have echoed the sentiment that "[t]he goal of ameliorating
the uglier side of a modern economy did not imply that all workers were
equally needful of protection."' 4 Congress, however, never defined these
exemptions from overtime pay, forcing courts to rely on conflicting inter-
pretive guidance promulgated by the Department of Labor (DOL).15 Un-
surprisingly, courts have proved inconsistent in applying these
exemptions, known as the "white-collar exemptions," within the complexi-
ties of the modern American workplace.' 6
Further complicating matters for both courts and employers, the
DOL revised its interpretative regulations regarding the white-collar ex-
emptions in 2004.'1 As a result, pharmaceutical companies have witnessed
a surge in collective actions filed by PSRs, alleging they were misclassified
as exempt from overtime pay.'" This issue is particularly important within
the Third Circuit because the majority of pharmaceutical manufacturers
14. Nicholson v. World Bus. Network, 105 F.3d 1361, 1363 (11th Cir. 1997);
see id. (discussing purpose of FLSA but noting that "Congress removed 'any em-
ployee employed in a bona fide executive, administrative, or professional capacity
... or in the capacity of outside salesman' from the FLSA's strictures" (quoting 29
U.S.C. § 213(a) (1))); see also Defining and Delimiting the Exemptions for Execu-
tive, Administrative, Professional, Outside Sales and Computer Employees, 69 Fed.
Reg. at 22,123-24 (discussing rationale for white-collar exemptions).
15. See 29 U.S.C. §§ 203, 213 (defining employee broadly, but failing to define
"executive, administrative, and professional" employee exemptions from overtime
pay); id. § 204(b) (granting DOL authority to interpret statute's provisions from
"time to time"); Malamud, supra note 10, at 2289 ("Instead, the statute expressly
authorized the Department of Labor to issue regulations interpreting these
terms-making the choice to locate the decision in the agency rather than in the
courts.").
16. See Malamud, supra note 10, at 2220 (discussing how enumerated exemp-
tions regarding executive, administrative, and professional employees are known
as "FLSA's so-called 'white-collar exemptions'" and "are still the subject of contro-
versy"); see also Defining and Delimiting the Exemptions for Executive, Administra-
tive, Professional, Outside Sales and Computer Employees, 69 Fed. Reg. at 22,127
(implying that pre-2004 revisions were complicated and confusing, resulting in di-
vergent outcomes when applied in different factual scenarios).
17. See Defining and Delimiting the Exemptions for Executive, Administra-
tive, Professional, Outside Sales and Computer Employees, 69 Fed. Reg. at 22,122
(stating that revisions to white-collar exemptions were necessary because "work-
place changes over the decades and federal case law developments are not re-
flected in the [pre-2004] regulations"); THOMPSON PUBL'G GRP., FLSA SPECIAL
REPORT: DOL's NEW WHITE-COLLAR EXEMPTION RULES-WHAT EMPLOYERS NEED TO
KNow, at iii (2004), available at http://www.thompson.com/images/thompson/re-
ports/FLSAreport.pdf (discussing DOL's "sweeping changes to its longstanding
regulations implementing the 'white-collar' exemptions").
18. See Tilson, supra note 12, at 685 (discussing how "[t]he 21st century has
brought increased attention to the [FLSA] ... [w]ith the advent of the 'virtual
workplace,' telecommuting by employees, and flexible scheduling arrangements");
id. (asserting rise in suits brought by "groups of aggrieved workers seeking seven-
figure damage awards ... based on alleged misclassification"); Daniel V. Yager &
Sandra J. Boyd, Reinventing the Fair Labor Standards Act to Support the Reengineered
Workplace, 11 LAB. LAw. 321, 331 (1996) ("Few, if any, areas of employment law
have proven themselves less adaptable to an evolving work force than the so-called
white-collar exemption to the FLSA.").
676
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are located in the northeast corridor.'9 This concern, however, is not
unique to PSRs; rather, it is representative of countless other employees in
the modern American workforce who do not work conventional "nine-to-
five" jobs. 20
This Casebrief recognizes the current division developing among
courts concerning whether PSRs have been wrongly misclassified as ex-
empt from overtime pay.2 ' Despite the Second Circuit's more recent rul-
ing in In re Novartis Wage and Hour Litigation,22 this Casebrief identifies the
19. See 2011-2012 Pharm Country: The Northeast Corridor's Life Science Community,
BIoSPACE.coM, http://www.biospace.com/hotbed map.aspx?ContentEntitylD=
934 (last updated 2011) (depicting map of pharmaceutical manufacturers, which
heavily populate Pennsylvania and New Jersey); States Fact Sheets, in DEP'T OF
HEALTH & HUMAN SERVS., U.S. FOOD AND DRUG ADMINISTRATION, FISCAL YIR 2010:
JUSTIFICATION OF ESTIMATES FOR APPROPRIATIONS COMMIFTEES 325 (2009), available
at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/
BudgetReports/UCM153517.pdf (recognizing that pharmaceutical industry has
strong presence in Pennsylvania and NewJersey).
20. See Ashley M. Rothe, Comment, Blackbenys and the Fair Labor Standards Act:
Does a Wireless Ball and Chain Entitle White-Collar Workers to Overtime Compensation?, 54
ST. Louis U. L.J. 709, 711 (2010) (drawing parallel between modem workplace
demands on white-collar workers and industrial sweatshops (citing JILL ANDRESKY
FRASER, WHITE-COLLAR SWEATSHOP: THE DETERIORATION OF WORK AND ITS REwARDS
IN CORPORATE AMERICA (2001))).
21. See Smith v. Johnson & Johnson, No. 06-4787 (JLL), 2008 WL 5427802
(D.N.J. Dec. 30, 2008) (finding PSRs met administrative employee exemption
(AEE) but failing to address whether PSRs also qualified for outside sales employee
exemption (OSEE)), affd, 593 F.3d 380 (3d Cir. 2010); Cote v. Burroughs
Wellcome Co., 558 F. Supp. 883, 887 (E.D. Pa. 1982) (holding that "detail person"
for pharmaceutical manufacturer qualified was exempt under AEE). Although
both district courts within the Third Circuit that addressed the exemption status of
PSRs determined that PSRs were exempt from the FLSA's overtime pay require-
ments, the three district courts within the Second Circuit were not as consistent.
Compare In re Novartis Wage and Hour Litig., 593 F. Supp. 2d 637 (S.D.N.Y. 2009)
(holding PSRs were exempt under both AEE and OSEE), vacated, 611 F.3d 141 (2d
Cir. 2010), cert. denied, 131 S. Ct. 1568 (2011), with Ruggeri v. Boehringer In-
gelheim Pharm., Inc., 585 F. Supp. 2d 254 (D. Conn. 2008) (determining that
PSRs were not exempt under OSEE), and Amendola v. Bristol-Myers Squibb Co.,
558 F. Supp. 2d 459 (S.D.N.Y. 2008) (finding PSRs were not exempt under OSEE
but would likely be exempt under AEE). Although the Third Circuit in Smith af-
firmed the district court's decision, the Second Circuit's decision in Novartis both
reversed the district court's holding and contradicted the Third Circuit's decision
in Smith. Compare Smith, 593 F.3d 280 (affirming district court's decision that PSRs
were exempt under AEE), with Novartis, 611 F.3d 141 (holding PSRs were not ex-
empt under either OSEE or AEE). As a result, more recent decisions within the
Second and Third Circuits have followed their respective circuit holdings, deepen-
ing the split. Compare Baum v. AstraZeneca LP, 605 F. Supp. 2d 669 (W.D. Pa.
2009) (asserting PSRs qualified for AEE), affd, 372 F. App'x 246 (3d Cir. 2010),
cert. denied, 131 S. Ct. 332 (2010), andjackson v. Alpharma, Inc., No. 07-3250 (GEB-
DEA), 2010 WL 2869530 (D.N.J. July 19, 2010) (following Third Circuit's decision
in Smith and declaring PSRs exempt under AEE), with Kuzinski v. Schering Corp.,
604 F. Supp. 2d 385 (D. Conn. 2009) (stating PSRs were not exempt from FLSA
overtime pay requirements), affJd, 384 F. App'x 17 (2d Cir. 2010), cert. denied, 131
S. Ct. 1567 (2011).
22. 611 F.3d 141 (2d Cir. 2010), cert. denied, 131 S. Ct. 1568 (2011).
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Third Circuit's decision in Smith v. Johnson & Johnson23 as controlling.24
Part II examines the white-collar exemptions both before and after the
DOL's 2004 revisions and includes an account of the DOL's interpretive
guidance. 25 Additionally, Part II discusses the foundational district court
decisions and the Third Circuit's approach pre-Smith.2 6 Acknowledging
the Third Circuit as the first circuit court to address the exemption status
of PSRs, Part III characterizes the Third Circuit's decision in Smith as a
corollary to the district court's decision.2 7 Part III also distinguishes the
Third Circuit's approach as demonstrating unprecedented willingness to
consider the realities of the pharmaceutical industry and to challenge the
"controlling weight" of past precedent.2 8 Part IV analyzes the Third Cir-
cuit's decision in Smith in light of the Second Circuit's conflicting decision
in Novartis and exposes the DOL's influence on subsequent decisions as
undeserved. 29 Part IV also examines the impact of the circuit split on the
pharmaceutical industry and forecasts the impact of the Obama Adminis-
tration's pledge to target employee misclassification.o Finally, Part V
translates the Third Circuit's analysis in Smith into practical strategies for
employers and practitioners.3'
II. MEDICAL HISTORY ON FILE
On June 25, 1938, Congress enacted the FLSA, which established a
national minimum wage and guaranteed "time-and-a-half" as overtime
23. 593 F.3d 280 (3d Cir. 2010).
24. Compare id. (incorporating realities of industry and recognizing past pre-
cedent as irrelevant due to DOL's revisions), with Novartis, 611 F.3d at 149 (per-
forming analysis of PSR's duties under both OSEE and AEE but according DOL's
amicus brief with controlling weight, which was essentially outcome-
determinative).
25. For a further discussion of the statutory framework of the FLSA's white-
collar exemptions, the AEE and OSEE pre- and post-2004, and the DOL's interpre-
tive guidance, see infra notes 32-66 and accompanying text.
26. For a further discussion of the judicial framework of district court deci-
sions prior to Smith and the Third Circuit's approach pre-Smith, see infra notes 67-
83 and accompanying text.
27. For a further discussion of the foundation for the Third Circuit's decision
in Smith, see infra notes 84-89, 97-109, and accompanying text.
28. For a further discussion of the Third Circuit's analysis in Smith, see infra
notes 110-17 and accompanying text.
29. For a further discussion of the Second Circuit's contradictory decision in
Novartis and how the circuit split has impacted subsequent decisions, see infra
notes 118-43 and accompanying text.
30. For a further discussion of the impact of both the circuit split and the
Obama Administration's 2011 efforts to back the DOL's fight against employee
misclassification, see infra notes 144-49 and accompanying text.
31. For a further discussion of strategies for employers and practitioners, see
infra notes 150-58 and accompanying text.
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pay.32 Congress, however, was clear that the reach of the minimum wage
and overtime pay protections was limited.33 Congress, therefore, recog-
nized the following types of "white-collar employees" as exempt from these
protections: (1) executive; (2) administrative; (3) professional; and (4)
outside sales.34 Although abstaining from defining the white-collar ex-
emptions, Congress delegated authority to the Secretary of Labor to pro-
vide interpretive guidance, which has taken the form of codified
regulations, opinion letters, and amicus briefs.3 5 Nevertheless, courts
have failed to consistently apply the DOL's interpretive guidance when
determining whether PSRs are "plainly and unmistakably within [the]
terms and spirit" of either the administrative employee exemption (AEE)
or outside sales employee exemption (OSEE). 36
A. Statutory Examination
Prior to 2004, the DOL's regulations consisted of somewhat ambigu-
ous multi-part tests to determine whether a PSR satisfied the requirements
for either the AEE or OSEE.3 7 Attempting to modernize and streamline
32. See FLSA, 29 U.S.C. §§ 201-19 (2006) (enumerating "Fair Labor Stan-
dards"); Brooklyn Say. Bank v. O'Neil, 324 U.S. 697, 707 n.18 (1945) (stating basic
goal of FLSA).
33. See 29 U.S.C. § 213 (listing exemptions to minimum wage and maximum
hour protections); Michael A. Faillace, Automatic Exemption of Highly-Paid Employees
and Other Proposed Amendments to the White-Collar Exemptions: Bringing the Fair Labor
Standards Act into the 21st Century, 15 LAs. LAw. 357, 361 (2000) (asserting that
white-collar exemptions demonstrate that FLSA "was never intended to cover all
employees").
34. See 29 U.S.C. § 213 (identifying "any employee employed in a bona fide
executive, administrative, professional, . . . or in the capacity of an outside sales-
man" as exempt from overtime pay under FLSA); Faillace, supra note 33, at 361
(explaining that white-collar exemptions functioned as "line-drawing tools be-
tween the hourly blue-collar clerical and line-workers, and the salaried white-collar
supervisors and managers").
35. See 29 U.S.C. § 213(a) (1) (delegating power to Administrator (now Secre-
tary of Labor) to "define[ ] and delimit[ ]" white-collar exemptions). Congress
ensured that the boundaries of these exemptions would not remain static and
charged the Secretary of Labor with periodically revising and adjusting the codi-
fied regulations to comport with the evolving workplace. See id. § 204(b) (asserting
Administrator had discretion to interpret and update exemptions); see also Auer v.
Robbins, 519 U.S. 452, 463 (1997) (discussing Secretary of DOL's authority to re-
solve statutory ambiguities); Chevron, U.S.A., Inc. v. Natural Res. Def. Council,
Inc., 467 U.S. 837, 842-43 (1984) (affirming agency's authority to interpret
statute).
36. Arnold v. Ben Kanowsky, Inc., 361 U.S. 388, 392 (1960) (discussing diffi-
culty of applying exemptions). Courts, however, cannot interpret the white-collar
exemptions based solely on their face value. See Nicholson v. World Bus. Network,
105 F.3d 1361, 1364 (11th Cir. 1997) ("To read the FLSA blindly, without appreci-
ation for the social goals Congress sought, would also do violence to the FLSA's
spirit.").
37. See 29 C.F.R. §§ 541.2, 541.5 (2003) (enumerating pre-2004 AEE and
OSEE tests); see also A.H. Phillips, Inc. v. Walling, 324 U.S. 490, 493 (1945) (re-
minding courts to narrowly construe exemptions under FLSA); Gregory v. First
Title of Am., Inc., 555 F.3d 1300, 1307 (11th Cir. 2009) (warning that courts must
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the white-collar exemptions, the DOL revised the regulations in 2004 by
consolidating and clarifying the criteria for distinguishing between ex-
empt and nonexempt salaried employees.38 In addition to the pre- and
post-2004 revisions, the DOL has also supplied both solicited opinion let-
ters and unsolicited amicus briefs, which courts have typically accorded
with controlling weight when determining the exemption status of PSRs. 3 9
1. Pre-2004 Revisions
Prior to the DOL's 2004 revisions, the AEE consisted of a "long test"
and a "short test," each of which consisted of two subtests: (1) the "salary
basis test"; and (2) the "duties test."40 To satisfy the relevant provisions
under the AEE long test, a PSR was required to earn a minimum salary of
$155 per week and perform four pertinent duties: (1) primarily perform
"office or nonmanual work" "of substantial importance" "directly related
to management policies or general business" ("primary duty prong"); (2)
"customarily and regularly exercise [ ] discretion and independent judg-
ment" ("discretion and independent judgment prong"); (3) "perform[ ]
under only general supervision"; and (4) devote eighty percent of one's
workweek to the performance of exempt duties.41 Alternatively, to satisfy
the relevant provisions under the AEE short test, a PSR needed to: (1)
earn $250 per week and (2) satisfy both the primary duty prong and the
discretion and independent judgment prong.4 2
Unlike the AEE, the pre-20 0 4 OSEE consisted of a lone short test and
did not mandate a minimum salary.4 3 To satisfy the relevant provisions,
the OSEE required a PSR to be "customarily and regularly engaged away
from his employer's place . . . of business" for the purpose of either: (1)
"navigate a course between a rock and a hard place" and "narrowly construe the
exemption[s] without diminishing the spirit of its parent legislation").
38. See Roe-Midgett v. CC Servs., Inc., 512 F.3d 865, 870 (7th Cir. 2008) (dis-
cussing how 2004 revisions simplified white-collar exemptions); Defining and De-
limiting the Exemptions for Executive, Administrative, Professional, Outside Sales
and Computer Employees, 69 Fed. Reg. 22,122, 22,126 (Apr. 23, 2004) (explaining
that 2004 revisions were made to streamline, organize, and update regulations).
39. See Chevron, 467 U.S. at 844 ("[L]egislative regulations are given control-
ling weight unless they are arbitrary, capricious, or manifestly contrary to the stat-
ute." (citing United States v. Morton, 467 U.S. 822, 834 (1984))).
40. See 29 C.F.R. § 541.2 (2003) (detailing pre-2004 requirements necessary to
satisfy AEE under either "long test" or "short test"); Side-By-Side: Overtime Security for
21st Century Workers, U.S. DEP'T OF LABOR [hereinafter Regulation Comparison Chart],
http://www.dol.gov/whd/regs/compliance/fairpay/side-by-sidePF.htm (last vis-
ited Aug. 29, 2011) (comparing old and new white-collar exemption tests).
41. See 29 C.F.R. § 541.2 (2003) (specifying salary and duty requirements
under AEE long test).
42. See id. (detailing salary and duty requirements of AEE short test); Regula-
tion Comparison Chart, supra note 40 (summarizing pre-2004 AEE "short test").
43. Compare 29 C.F.R. § 541.5 (2003) (requiring that employee must only
meet requirements of pre-2004 OSEE short test), with 29 C.F.R. § 541.2 (2003)
(providing that employee can meet pre-2004 AEE by satisfying requirements of
either long test or short test).
[Vol. 56: p. 671680
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"[m] aking sales within the meaning of section 3(k) of the [FLSA]" or (2)
[o]btaining orders or contracts."4 4 Further, a PSR needed to devote
eighty percent of the workweek to exempt duties.4 5 Additionally, the pre-
2004 OSEE included an "indicia of sales" test, which was often used be-
cause PSRs perform a combination of sales and promotional work.4 6
2. DOL's 2004 Revisions
Acknowledging that the framework of the pre-200 4 white-collar ex-
emptions "reflect[ed] the best evidence of the American workplace a half-
century ago," the DOL adapted the regulations to mirror the modern
workplace. 47 Following the revisions, the AEE consisted of a single stan-
dard test, which fundamentally maintained the pre-2004 "salary basis test"
and "duties test."4 8 To satisfy the revised salary requirement, a PSR must
now earn a minimum of $455 per week, or $22,660 per year.4 9 Addition-
ally, the revisions borrowed the pre-2004 dual-prong duties test, but added
a qualifying phrase to the primary duty prong, which further requires a
PSR to exercise one's primary duty "with respect to matters of
significance."5 0
In addition to providing examples of administrative exemptions, the
2004 revisions used simplified language to flesh out the respective require-
44. See 29 C.F.R. § 541.5 (2003) (detailing pre-2004 requirements necessary to
satisfy OSEE short test); Regulation Comparison Chart, supra note 40 (summarizing
pre-2004 OSEE short test).
45. See 29 C.F.R. § 541.5(b) (2003) (requiring that no more than twenty per-
cent of employee's work could be nonexempt); Regulation Comparison Chart, supra
note 40 (requiring that majority of employee's duties constitute exempt work).
46. See 29 C.F.R. § 541.505(e) (2003) (listing "indicia of sales" factors, which
were considered when employee performed combination of selling and promo-
tional work). But see Nielson v. Devry, Inc., 302 F. Supp. 2d 747, 756-58 (W.D.
Mich. 2003) (arguing that indicia of sales factors cannot be considered in
isolation).
47. See Defining and Delimiting the Exemptions for Executive, Administra-
tive, Professional, Outside Sales and Computer Employees, 69 Fed. Reg. 22,122,
22,124 (Apr. 23, 2004) (concluding that pre-2004 regulations were outdated be-
cause "the structure of the workplace, the type of jobs, the education level of the
workforce, and the workplace dynamics of an industrial economy . . . has long
been altered").
48. Compare 29 C.F.R. § 541.200 (2005) (enumerating single AEE test), with
29 C.F.R. § 541.2 (2003) (delineating two alternative tests to satisfy pre-2004 AEE:
(1) "long test" or (2) "short test").
49. See 29 C.F.R. § 541.200 (2005) (specifying salary requirements for post-
2004 AEE test); Regulation Comparison Chart, supra note 40 (comparing salary re-
quirements for pre-2004 and post-2004 AEE test).
50. Compare 29 C.F.R. § 541.200 (2005) (adding qualifying phrase of "with re-
spect to matters of significanci' to primary duty prong of duties test (emphasis ad-
ded)), with 29 C.F.R. § 541.205(a) (2003) (limiting "directly related" portion of
primary duty prong to employees who perform work "of substantial importance to the
management or operation of the business" (emphasis added)).
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ments of the AEE's modified dual prongs.5 ' The DOL, however, may have
traded one problem for another as courts are now struggling to gauge
whether PSRs exercise their primary duties "with respect to matters of sig-
nificance."5 2 Further complicating this determination is the DOL's sug-
gestion that PSRs must now additionally meet two or three factors, which
are delineated in the discretion and independent judgment prong.5 3
Similar to the revised AEE, the revised OSEE preserves the framework
of the pre-2004 paradigm. 54 Retaining the former short test, the OSEE
still requires a PSR's primary duty to consist of either "making sales" or
"obtaining orders."5 5 Additionally, the revised OSEE maintains the sup-
plementary requirement that a PSR must "customarily and regularly en-
gage[ ] [in work] away from the employer's place ... of business" to satisfy
the exemption.5 6
Although the revised OSEE departs from reliance on the "indicia of
sales" test, new litigation surrounds the OSEE's modified focus on whether
"the employee, in some sense, has made sales."57 As a result, courts have
51. See 29 C.F.R. § 541.203 (2005) (providing AEE examples); id. §§ 541.201,
541.202 (elaborating on requirements of dual prongs).
52. SeeJirak v. Abbott Labs., Inc., 716 F. Supp. 2d 740, 751 (N.D. Ill. 2010)
(finding that PSRs do not exercise independent judgment with respect to matters
of significance); Ruggeri v. Boehringer Ingelheim Pharm., Inc., 585 F. Supp. 2d
254, 275 (D. Conn. 2008) (discussing court's uncertainty that PSR's "independent
judgments ... were exercised and made with respect to 'matters of significance'");
Amendola v. Bristol-Myers Squibb Co., 558 F. Supp. 2d 459, 476 (S.D.N.Y. 2008)
(reasoning that PSRs would likely satisfy AEE even though industry "circum-
scribe[s]" manner in which PSRs exercise independent judgment with respect to
matters of significance).
53. See 29 C.F.R. § 541.202(b) (2005) (providing non-comprehensive list of
ten examples that would satisfy "directly related" portion of primary duty prong);
Defining and Delimiting the Exemptions for Executive, Administrative, Profes-
sional, Outside Sales and Computer Employees, 69 Fed. Reg. 22,122, 22,143 (Apr.
23, 2004) (discussing non-exhaustive list of ten factors "to consider when deter-
mining whether an employee exercises discretion and independent judgment with
respect to matters of significance").
54. See 29 C.F.R. § 541.500 (2005) (specifying salary and duty requirements
needed to satisfy post-20 04 OSEE); Regulation Comparison Chart, supra note 40
(comparing pre-2004 and post-2004 OSEE test).
55. See 29 C.F.R. § 541.500 (2005) (stating that employees will satisfy post-
2004 OSEE by either "making sales within the meaning of Section 3(k) of [FLSA]"
or "obtaining orders or contracts for services or for the use of facilities for which a
consideration will be paid by the client or customer"); id. § 541.501 (providing
expansive interpretation of "making sales or obtaining orders"); see also FLSA, 29
U.S.C. § 203(k) (2006) (defining "sale").
56. 29 C.F.R. § 541.500 (2005) (delineating two requirements to satisfy post-
2004 OSEE test); id. § 541.502 (requiring that employee must also regularly work
"away from employer's place of business" to satisfy post-2004 OSEE test).
57. Compare Defining and Delimiting the Exemptions for Executive, Adminis-
trative, Professional, Outside Sales and Computer Employees, 69 Fed. Reg. at
22,162 ("An employer cannot [apply the outside sales exemption] unless it demon-
strates that the employee, in some sense, has made sales." (emphasis added)), and 29
C.F.R. § 541.500 (2005) (removing indicia of sales test), with 29 C.F.R.§ 541.505(e) (2003) (listing indicia of sales factors). Courts, however, have strug-
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faced the challenge of deciding whether the doctrine of ejusdem generis
precludes expansion of the definition of "sale."5 8 Courts, therefore, have
tended to err on the side of caution, finding PSRs as exempt under the
AEE rather than the OSEE.5 9
3. DOL's Interpretive Guidance
Although FLSA requirements are set by statute and "define [d] and
delimit[ed]" in the regulations, the DOL provides additional interpretive
guidance through opinion letters and amicus briefs.60 Courts, employers,
and employees, in turn, rely on this guidance to determine how the re-
quirements apply to specific factual situations.6 1 Until recently, the DOL
selectively responded to written requests submitted by employers, inquir-
gled to deal with the implications of the revised OSEE test. See, e.g., Ackerman v.
Coca-Cola Enters., Inc., 179 F.3d 1260, 1265 (10th Cir. 1999) (holding that OSEE
cannot apply "if the employee in question does not actually consummate the
sale"); In re Novartis Wage and Hour Litig., 593 F. Supp. 2d 637, 650 (S.D.N.Y.
2009) (finding that PSRs "make sales in the sense that sales are made in the phar-
maceutical industry"), vacated, 611 F.3d 141 (2d Cir. 2010), cert. denied, 131 S. Ct.
1568 (2011); Ruggeri, 585 F. Supp. 2d at 270-72 (finding that indicia of sales could
not be used as alternative test).
58. See 29 U.S.C. § 203(k) (defining "sale"); Circuit City Stores, Inc. v. Adams,
532 U.S. 105, 138 (2001) (defining doctrine of ejusdem generis as "interpretive
maxim" which states that "when specific terms are followed by a general one, the
latter is meant to cover only examples of the same sort as the preceding specifics");
Novartis, 611 F.3d at 153 (discussing "ejusdem generis-type interpretation" of sale).
59. See generally Jackson v. Alpharma, Inc., No. 07-3250 (GEB-DEA), 2010 WL
2869530 (D.N.J. July 19, 2010) (finding PSRs exempt under AEE); Baum v. As-
traZeneca LP, 605 F. Supp. 2d 669, 687 (W.D. Pa. 2009) (same), aff'd, 372 F. App'x
246 (3d Cir. 2010), cert. denied, 131 S. Ct. 332 (2010); Smith v. Johnson &Johnson,
No. 06-4787 (JLL), 2008 WL 5427802 (D.N.J. Dec. 30, 2008) (finding PSRs exempt
under AEE but not OSEE), affd, 593 F.3d 280 (3d Cir. 2010).
60. See 29 U.S.C. §§ 201-19 (enacting statute); id. § 213(a)(1) (delegating
power to Secretary of Labor to "define[ ] and delimit[ ]" white-collar exemptions);
29 C.F.R. § 541 (2003) (interpreting FLSA through regulations). The DOL, how-
ever, has also issued supplementary guidance in opinion letters and amicus briefs.
See, e.g., WAGE & HOUR Div., DEP'T OF LABOR, OPINION LETTER FLSA2006-16 (May
22, 2006), available at 2006 WL 1698305 (responding to inquiry concerning
whether employees who solicit charitable donations are exempt under OSEE);
WAGE & HOUR Div., DEP'T OF LABOR, OPINION LETFER FLSA 2000-23 (July 17,
2000), available at 2000 DOLWH LEXIS 23 (addressing concern as to whether ex-
ecutive secretary was exempt under AEE); Brief for the Secretary of Labor as Ami-
cus Curiae in Support of Plaintiffs-Appellants, Novartis, 611 F.3d 141 (No. 09-0437-
cv), 2009 WL 3405861 (arguing that PSRs should not be exempt from overtime
pay); Brief for the Secretary of Labor as Amicus Curiae in Support of Plaintiffs-
Appellants, Christopher v. SmithKline Beecham Corp., 635 F.3d 383 (9th Cir.
2011) (No. 10-15257), 2010 WL 5854250 [hereinafter Christopher Brief] (same).
61. See Novartis, 611 F.3d at 144 (agreeing with views expressed in Secretary of
DOL's amicus brief); Cote v. Burroughs Wellcome Co., 558 F. Supp. 883, 886 n.2
(E.D. Pa. 1982) (stating that DOL's 1945 Opinion Letter was not dispositive but
reasoning that it provided "some further evidence" to determine that "detail per-
son" was exempt from overtime pay).
2012] CAsEBRIEF 6)83
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ing about the exemption status of particular employees based on stipu-
lated facts. 62
Because the DOL determined that it will no longer provide fact-spe-
cific opinion letters to employers, the Third Circuit's decision in Smith
provides direction for other courts seeking to challenge the controlling
deference typically afforded to both opinion letters and amicus briefs.63
Although district and circuit courts have previously relied on both of these
for guidance, neither have the force and effect of law and, therefore, can-
not warrant the same degree of deference accorded to the regulations. 64
Additionally, the Smith decision provides a paradigm for courts wishing to
break away from precedential cases; the Third Circuit recognized that
"controlling" cases often relied on supplementary interpretive guidance
based on the pre-2004 regulations (now outdated). 65 Courts, therefore,
must now be wary of cases decided prior to the DOL's 2004 revisions as
well as any interpretive guidance that provided the basis of those
holdings. 66
B. Judicial Examination
1. District Court Decisions Pre-Smith
Prior to the Third Circuit's decision, only two district courts within
the circuit specifically addressed the exemption status of PSRs. 67 Both dis-
trict courts, however, were hesitant to find PSRs exempt under the OSEE
62. See Wage and Hour Division (WHD): Rulings and Interpretations, U.S. DEP'T OF
LABOR, http://www.dol.gov/whd/opinion/opinion.htm (last visited Feb. 15, 2011)
(stating that DOL will no longer issue fact-specific opinion letters, implying that
they were inefficient and unproductive).
63. See DOL Replaces Fact-Specific Opinion Letters with More Broadly Applicable "Ad-
ministrator Interpretations", THOMPSON, Mar. 24, 2010, http://www.thompson.com/
public/printpagejsp?id=2730&pageid=newsbrief (discussing how DOL will now
"provide general interpretation of the laws and regulations applicable to all");
Wage and Hour Division (WHD): Rulings and Interpretations, supra note 62 (asserting
that DOL will now issue "Administrator Interpretations" instead of fact-specific
opinion letters).
64. See Auer v. Robbins, 519 U.S. 452, 461 (1997) (discussing controlling
weight accorded to interpretations by Secretary of DOL); Chevron, U.S.A., Inc. v.
Natural Res. Def. Council, Inc., 467 U.S. 837, 843-44 (1984) (explaining why Secre-
tary's regulations are accorded deferential authority). But see Schaefer-LaRose v.
Eli Lilly & Co., No. 1:07-cv-1133-SEB-TAB, 2010 WL 3892464, at *2 (S.D. Ind. Sept.
29, 2010) (refusing to revisit exemption analysis of PSR at issue on basis of amicus
brief that DOL submitted in Novartis); Christopher v. SmithKline Beecham Corp.,
No. CV-08-1498-PHX-FJM, 2010 WL 396300, at *1 (D. Ariz. Feb. 1, 2010) (explain-
ing why DOL's amicus brief was not entitled to controlling deference), aff'd, 635
F.3d 383, cert. granted, No. 11-204, 2011 WL 3608968 (U.S. 2011).
65. See Smith v.Johnson & Johnson, 593 F.3d 280, 286 (3d Cir. 2010) (depart-
ing from prior precedent), affg, No. 06-4787 (JLL), 2008 WL 5427802, at *8
(D.N.J. Dec. 30, 2008) (explaining why court departed from prior precedent in
Third Circuit).
66. See id. (establishing new precedent).
67. See Smith, 2008 WL 5427802, at *4-13 (addressing whether PSR at issue was
exempt from overtime pay under either OSEE or AEE); Cote v. Burroughs
684 [Vol. 56: p. 671
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and, instead, held that PSRs qualified for exemption status under the
AEE. 68 Interestingly, one of the district courts relied heavily on a 1945
DOL Opinion Letter, which stated that medical "detailers" were exempt
from the FLSA, in order to determine that the PSR at issue was an admin-
istrative employee and, therefore, exempt from overtime pay require-
ments. 69 In district courts outside of the Third Circuit, pharmaceutical
companies have enjoyed similar success pre-Smith, winning six out of eight
cases and finding PSRs exempt under the AEE, OSEE, or both.70
2. Third Circuit's Approach Pre-Smith
Prior to the Third Circuit's decision in Smith, Martin v. Cooper Electric
Supply Co. 71 controlled as precedent within the circuit regarding the
AEE.1 2 Applying Icicle Seafoods, Inc. v. Worthington,73 the Third Circuit in
Martin determined that an employee's exemption status under the FLSA is
a question of law when the employee's job responsibilities are not dis-
puted.74 Borrowing the rationales in Arnold v. Ben Kanowsky, Inc.7 5 and
Wellcome Co., 558 F. Supp. 883, 885-88 (E.D. Pa. 1982) (addressing whether phar-
maceutical detail person at issue was exempt under AEE).
68. See Smith, 2008 WL 5427802, at *13 (finding PSR exempt under AEE but
not OSEE); Cote, 558 F. Supp. at 887 (finding detail person was exempt under
AEE).
69. See Cote, 558 F. Supp. at 886 n.2 (stating that DOL's 1945 Opinion Letter
provided additional evidence to support court's conclusion); Wage & Hour Div.,
Dep't of Labor, Opinion Letter 1943-48, 1 Lab. L. Rep. (CCH) 1 33093 (stating
that medical "detailists" are exempt from overtime pay under FLSA).
70. See In re Novartis Wage and Hour Litig., 593 F. Supp. 2d 637, 637 (S.D.N.Y.
2009) (finding PSR to be exempt under both OSEE and AEE), vacated, 611 F.3d
141 (2d Cir. 2010), cert. denied, 131 S. Ct. 1568 (2011); Rivera v. Schering Corp.,
No. CV 08-1743-GW(JCx), 2008 WL 6953955, at *3-4 (C.D. Cal. Aug. 14, 2008)
(determining that PSR satisfied OSEE); Brody v. AstraZeneca Pharm., LP, No. CV
06-6862 ABC (MANx), 2008 WL 6953957, at *9 (C.D. Cal. June 11, 2008) (same);
Menes v. Roche Labs., Inc., No. 2:07-cv-01444-ER-FFMx, 2008 WL 6600518, at *2
(C.D. Cal.Jan. 7, 2008) (same); Barnick v. Wyeth, 522 F. Supp. 2d 1257, 1264 (C.D.
Cal. 2007) (same); D'Este v. Bayer Corp., No. CV 07-3206-JFW (PLAx), 2007 WL
6913682, at *5 (C.D. Cal. Oct. 9, 2007) (finding that PSR qualified for OSEE and,
therefore, it was unnecessary to address whether PSR additionally qualified for
AEE). But see Ruggeri v. Boehringer Ingelheim Pharm., Inc., 585 F. Supp. 2d 254
(D. Conn. 2008) (concluding that PSR was not exempt under OSEE); Amendola v.
Bristol-Myers Squibb, Co., 558 F. Supp. 2d 459, 462 (S.D.N.Y. 2008) (establishing
that although PSR was not exempt under OSEE, PSRs were likely subject to AEE).
71. 940 F.2d 896 (3d Cir. 1991).
72. See Smith v. Johnson &Johnson, 593 F.3d 280, 285 (3d Cir. 2010) (discuss-
ing previous Third Circuit decision on point); Smith, 2008 WL 5427802, at *8-13
(discussing reliance on pre-2004 regulations by precedential case in Third Circuit
(citing Martin, 940 F.2d 896)).
73. 475 U.S. 709 (1986).
74. See id. at 714 ("The question whether their particular activities excluded
them from the overtime benefits of the FLSA is a question of law."); Martin, 940
F.2d at 900 (discussing how court can review district court's application of facts).
75. 361 U.S. 388 (1960).
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Idaho Sheet Metal Works, Inc. v. Wirtz,76 the Third Circuit in Martin reasoned
that white-collar exemptions must "be 'narrowly construed against the em-
ployer[ ]"' and that the employer bears the burden of proof regarding the
exemption status of employees, respectively.7 7 Additionally, the court re-
lied on the "administrative-production work dichotomy" in the pre-2004
regulations, finding that inside salespersons employed by a wholesale dis-
tributor were not exempt under the AEE because they did not satisfy the
primary duty prong by either "promoting sales" or performing "work of
substantial importance."78
Because Martin did not address the OSEE, the Third Circuit pre-Smith
relied on the Tenth Circuit's decision in Jewel Tea Co. v. Williams,7 9 which
set forth the rationale of the OSEE.8 0 Relying on the indicia of sales test
from the pre-2004 regulations, the Tenth Circuit in jewel Tea held that the
route salesperson was exempt from the FLSA overtime pay require-
ments.8 1 Unlike Martin, however, the rationale applied in jewel Tea re-
mains instructive because the indicia of sales test is still viewed as an
important tool to guide courts despite being removed from the revised
regulations.8 2 The Third Circuit in Smith, therefore, recognized the need
to distinguish Martin and look beyond the confines of the Third Circuit
for AEE guidance regarding PSRs.8 3
III. INrMAL DIAGNOSIS
The district court in Smith was the first district court in the Third Cir-
cuit to address the exemption status of PSRs in almost two decades.84
76. 383 U.S. 190 (1966).
77. Martin, 940 F.2d at 900 (quoting Wirtz, 383 U.S. at 206) (citing Arnold, 361
U.S. at 392).
78. See Martin, 940 F.2d at 901 (italics omitted) (affirming district's court use
of administrative-production work dichotomy); 29 C.F.R. § 541.205(a) (2003) (es-
tablishing importance of analyzing work as administrative or productive); id.§ 541.205(b) (explaining what would constitute administrative, as opposed to pro-
ductive, work).
79. 118 F.2d 202 (10th Cir. 1941).
80. See Martin, 940 F.2d at 900 (analyzing whether employee was exempt
under AEE only); jewel Tea, 118 F.2d at 207-08 (providing paradigm of OSEE).
81. See Jewel Tea, 118 F.2d at 208 (paralleling indicia of sales test from pre-
2004 regulations).
82. See In re Novartis Wage and Hour Litig., 593 F. Supp. 2d 637, 648 (S.D.N.Y.
2009) (discussing rationale expressed in jewel Tea), vacated, 611 F.3d 141 (2d Cir.
2010), cert. denied, 131 S. Ct. 1568 (2011). Although the post-2004 regulations do
not explicitly contain the indicia of sales test, it has an implied presence. See Defin-
ing and Delimiting the Exemptions for Executive, Administrative, Professional,
Outside Sales and Computer Employees, 69 Fed. Reg. 22,122, 22,124 (Apr. 23,
2004) (echoing jewel Tea's rationale, giving it continued relevance).
83. See Smith v. Johnson & Johnson, 593 F.3d 280, 286 (3d Cir. 2010) (af-
firming that Martin was inapplicable because it was "distinguishable on the facts").
84. See Smith v. Johnson &Johnson, No. 06-4787 (JLL), 2008 WL 5427802, at
*12 (D.N.J. Dec. 30, 2008) (determining that PSRs were exempt from overtime pay
under AEE), affd, 593 F.3d 280. Prior to Smith, the exemption status of PSRs had
686 [Vol. 56: p. 671
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Prior to Smith, PSRs challenged their exemption status in district courts
outside the Third Circuit on eight separate occasions.8 5 Although employ-
ers enjoyed the bulk of the success, the resulting judgments reflected a
reluctance to analyze whether PSRs were exempt from overtime pay under
the AEE in addition to the OSEE.86 The district court in Smith, however,
characterized these recent decisions as unpersuasive and, instead, held
that a PSR met the AEE but not the OSEE.8 7 Affirming the district court's
decision, the Third Circuit in Smith held that the PSR satisfied the AEE
and, therefore, was properly classified as exempt from overtime pay under
the FLSA. 8 8 Unlike the district court, however, the Third Circuit did not
address whether the PSR at issue also qualified for the OSEE.8 9
A. Patty Lee Smith's Self-Diagnosis
From April 2006 to October 2006, Patty Lee Smith worked as a Senior
Professional Sales Consultant for Johnson & Johnson (J & J), then the
second-largest company in the pharmaceutical industry.9 0 J &J employed
Smith, as well as thousands of other PSRs, to promote its products to physi-
cians according to specific company directives and industry regulations.9"
not been addressed by any district court within the Third Circuit in twenty-six
years. Compare id. (holding PSRs exempt under AEE), with Cote v. Burroughs
Wellcome Co., 558 F. Supp. 883, 883 (E.D. Pa. 1982) (holding that "detail person"
was exempt under AEE).
85. For citation to the eight cases that were decided prior to Third Circuit's
decision in Smith, see supra note 70 and accompanying text.
86. See, e.g., Smith, 2008 WL 5427802 (arguing it was unnecessary to explore
whether PSRs satisfied additional exemptions); Amendola v. Bristol-Myers Squibb
Co., 558 F. Supp. 2d 459, 477 (S.D.N.Y. 2008) (failing to explore other exemptions
despite insinuating that PSRs would likely meet AEE); D'Este v. Bayer Corp., No.
CV 07-3206-JFW (PLAx), 2007 WL 6913682 (C.D. Cal. Oct. 9, 2007) (examining
whether PSR satisfied OSEE, but not AEE).
87. See Smith, 2008 WL 5427802, at *6 (discussing why district court decisions
outside of Third Circuit were irrelevant). Compare id. at *4-12 (analyzing PSR
under both OSEE and AEE and determining that PSR satisfied AEE but not
OSEE), with Rivera v. Schering Corp., No. 08-1743-gw(JCx), 2008 WL 6953955
(C.D. Cal. Aug. 14, 2008) (analyzing PSR under OSEE only); Brody v. AstraZeneca
Pharm., LP, No. CV 06-6862 ABC (MANx), 2008 WL 6953957 (C.D. Cal. June 11,
2008) (same); Menes v. Roche Labs., Inc., No. 2:07-cv-01444-ER-FFMx, 2008 WL
6600518 (C.D. Cal. Jan. 7, 2008) (same); Barnick v. Wyeth, 522 F. Supp. 2d 1257
(C.D. Cal. 2007) (same); D'Este, 2007 WL 6913682 (same).
88. See Smith, 593 F.3d at 282 (granting summary judgment for employer and
determining that PSR satisfied AEE).
89. Compare id. at 286 n.4 (acknowledging that Third Circuit affirmed district
court's decision without addressing OSEE), with Smith, 2008 WL 5427802, at *4-12
(analyzing both OSEE and AEE).
90. See Smith, 2008 WL 5427802, at *1 (discussing Patty Lee Smith's job title,
employer, and length of employment); see also Fortune 500 2006: Industry-
Pharmaceuticals, CNNMONEY, http://money.cnn.com/magazines/fortune/for-
tune500/2006/industries/Pharmaceuticals/1.html (last updated Apr. 17, 2006)
(listingJ &J as second largest pharmaceutical company in 2006).
91. See 21 C.F.R. § 203.20 (1988) (prohibiting direct sales of prescription
drugs from PSRs to prescribers); Smith, 2008 WL 5427802, at *1-2 (explaining na-
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Specifically, Smith promoted Concerta, a Schedule II controlled substance
used to treat attention-deficit hyperactivity disorder (ADHD), to company-
identified target physicians using company-approved sales aids and "pre-
pared 'messages."' 9 2 Smith, however, emphasized that she worked mostly
unsupervised and exercised discretion to develop and implement a "strate-
gic plan," which served as a guide for how Smith planned her "calls," de-
veloped her relationships, tailored her sales pitches, and allocated her
budget.9 3 Although Smith planned and executed her business strategy for
a base salary of $66,000, J & J reserved discretion to award Smith with a
supplementary "bonus" if she achieved the requisite sales quotas.94 After
totaling the hours spent on her sales efforts, however, Smith believed that
she was entitled to more than incentive compensation and brought action
against her employer, seeking overtime pay under the FLSA.95
B. The District Court's Differential Diagnosis
Confronted with the issue of the exemption status of PSRs, the district
court in Smith first analyzed the facts under the OSEE.9 6 Notwithstanding
the recent district court cases addressing this issue, the court held that
these decisions did not provide persuasive guidance to determine whether
Smith was exempt as an outside salesperson under the FLSA.9 7 Instead,
the court relied on the rationale of Ruggeri v. Boehringer Ingelheim
Pharmaceuticals, Inc.98 and the Third Circuit's binding precedent of con-
struing exemptions narrowly, concluding that Smith's obligations as a PSR
could not be reconciled with the "standard business-to-business sales posi-
ture of Smith's employment and identifying Smith's role as "obtaining a commit-
ments [sic] from the physician (including a commitment to prescribe Concerta) in
order to increase sales via increasing prescriptions"); see also STUART 0. ScHWEIT-
ZER, PHARMACEUTICAL EcoNoMics AND PoLcy 87 (2d ed. 2007) (estimating that
there is "a ratio of 1 sales representative for every 9 doctors"); Saul, supra note 3
(asserting that there are approximately 90,000 PSRs nationwide).
92. See Smith, 593 F.3d at 282 (discussing company materials and resources
that J & J provided Smith); Smith, 2008 WL 5427802, at *1 (discussing Smith's
extensive training to promote Concerta).
93. See Smith, 593 F.3d at 282-83 (explaining that Smith "had some discretion"
despite industry regulations andJ &J's constraints); Smith, 2008 WL 5427802, at *2
(discussing how Smith was rarely supervised and essentially ran her own business).
94. See Smith, 593 F.3d at 283 (explaining J & J's discretion to award Smith
with bonus); Smith, 2008 WL 5427802, at *2 (asserting that bonus constituted "ap-
proximately 20% of Smith's total compensation").
95. See Smith, 593 F.3d at 283 ("After adding up the time she spent writing pre-
visit reports, driving, conducting the visits, writing post-visit reports, and complet-
ing other tasks, Smith worked more than eight hours per day.").
96. See Smith, 2008 WL 5427802, at *4-7 (analyzing Smith's duties as PSR
under OSEE).
97. See id. at *6 (explaining why district court cases decided outside of Third
Circuit were not persuasive).
98. 585 F. Supp. 2d 254 (D. Conn. 2008).
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tion" described in the OSEE.99 Despite recognizing that the FLSA regula-
tions did not account for sales transactions in the highly regulated nature
of the pharmaceutical industry, the court was unwilling to interpret the
ambiguity of Smith's role as a PSR as exempt under the OSEE. 0 0
The court, however, did not limit its analysis to the OSEE; the court
further considered whether Smith qualified for the AEE.10 Although
Smith urged the court to again adhere to binding Third Circuit precedent
and follow Martin, the court declined, reasoning that Martin relied on the
pre-2004 regulations and, therefore, was "inapposite to the text of the cur-
rent regulation at issue."' 0 2 Ironically, the court relied on Reich v. John
Alden Life Insurance Co.,o10 which was decided prior to the 2004 revisions,
and Amendola v. Bristol-Myers Squibb Co., 0 4 which determined that the PSR
at issue was non-exempt. 05 The court likened Smith to the marketing
representatives in Reich, reasoning that Smith's "role [was] as an educator
and promoter." 0 6 Although the court in Amendola determined that PSRs
did not satisfy the OSEE, Amendola held that PSRs were "likely subject to"
99. See Smith, 2008 WL 5427802, at *5-6 (stating that Ruggeri analysis was
more persuasive on the issue of how the FLSA outside sales exemption is applied"
than California district court cases); id. at *7 ("[T]he Third Circuit has empha-
sized that exemptions to the FLSA are to be narrowly construed against employers,
and . . . expanding the list of activities in the definition of sales to comprise the
kind of presentation of information engaged in by Smith .. . represent[s] a bridge
too far." (citing Davis v. Mountaire Farms, Inc., 453 F.3d 554, 556 (3d Cir. 2006)));
see also Madison v. Res. for Human Dev., Inc., 233 F.3d 175, 184 (3d Cir. 2000)
(asserting that "FLSA exemptions should be narrowly construed against the em-
ployer"); Friedrich v. U.S. Computer Servs., 974 F.2d 409, 412 (3d Cir. 1992) (dis-
cussing employers' burden of proof).
100. See Smith, 2008 WL 5427802, at *5 (stating that Smith's role as PSR "oc-
cupie[d] a somewhat ambiguous zone under the FLSA"); id. (discussing how FLSA
regulations "describe a standard business-to-business sales position, but fail to ad-
dress the thornier issues arising in highly regulated industries such as prescription
pharmaceuticals"); id. at *7 (acknowledging that physicians represent "a choke-
point in the sale of pharmaceuticals" but finding that nature of pharmaceutical
industry "insulates [physicians] from being amenable to 'sales"').
101. See id. at *7-12 (analyzing Smith's duties under AEE).
102. See id. at *8-9 (stating that Martin relied on pre-2004 regulations, which
required employees to "perform[ ] 'work of substantial importance"' (quoting 29
C.F.R. § 541.201(a) (2003))). Because the DOL revised this language in 2004, the
court asserted that Martin's holding was irrelevant. See id. (discussing difference
between pre-2004 and post-2004 regulations).
103. 126 F.3d 1 (1st Cir. 1997).
104. 558 F. Supp. 2d 459 (S.D.N.Y. 2008).
105. See Reich, 126 F.3d at 3 (determining that marketing representative was
exempt under pre-2004 AEE); Smith, 2008 WL 5427802, at *10-11 (describing Reich
and Amendola as "instructive" and "[t]he two cases most on-point"); Amendola, 558
F. Supp. 2d at 475-77 (finding analysis of Reich persuasive, distinguishing Martin,
and determining that PSR did not satisfy OSEE but would likely satisfy AEE).
106. See Reich, 126 F.3d at 11 (discussing district court's opinion, which recog-
nized that company's success depended on marketing representatives promoting
sales); Smith, 2008 WL 5427802, at *10 (drawing similarities between Smith's role
as PSR and marketing representatives' role in Reich).
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the AEE. 0 7 Developing this rationale, the district court in Smith con-
cluded that Smith's efforts to market and promote Concerta drove market
demand and, therefore, satisfied the AEE by substantially "affect[ing] op-
eration of 'a particular segment of the business."" 0 8 Additionally, the
court determined that Smith satisfied the requisite factors from the non-
exhaustive "ten factor test," which are required to satisfy the discretion
and independent judgment prong of the AEE test.10
C. The Third Circuit Concurs with Its Colleague
Allowing the district court to do most of the heavy lifting, the Third
Circuit in Smith essentially echoed the district court's holding.'1 0 Taking a
parallel approach, the Third Circuit began its discussion with a brief sum-
mary of the white-collar exemptions and how Third Circuit precedent in-
terpreted them."' The Third Circuit, however, condensed the district
court's efforts by skipping the OSEE inquiry and concentrating solely on
the AEE.11 2 Adopting the district court's reliance on Reich, the Third Cir-
cuit concluded that Smith satisfied the AEE because she developed a "stra-
tegic plan . . . to maximize sales" and exercised a "high level of planning
and foresight."' 13
107. See Amendola, 558 F. Supp. 2d at 462, 470, 477 (determining that PSRs
were not exempt under OSEE but that employer could likely demonstrate that
PSRs satisfy requirements for AEE).
108. See Smith, 2008 WL 5427802, at *10-11 (citation omitted) (discussing how
Smith, like marketing representatives in Amendola, impacted business operations);
see also id. at *11 (distinguishing Smith's role from sales representatives in Martin
(citing Martin v. Cooper Elec. Supply Co., 940 F.2d 896, 901, 903-04 (3d Cir.
1991))).
109. See Smith, 2008 WL 5427802, at *12 (explaining that Smith satisfied two
factors because her "work in driving the market for Concerta within her territory
'affect[ed] business operations to a substantial degree,' and she . . . '[wa]s involved
in planning long- or short-term business objectives' related to the marketing of
Concerta within her territory"); 29 C.F.R. § 541.202(b) (2005) (listing non-exclu-
sive factors, which can be used to determine whether employee meets require-
ments of discretion and independent judgment prong).
110. Compare Smith v. Johnson & Johnson, 593 F.3d 280, 286 n.4 (3d Cir.
2010) (affirming district court's decision that PSR was exempt under AEE without
addressing OSEE), with Smith, 2008 WL 5427802, at *4-13 (analyzing Smith's duties
under both OSEE and AEE).
111. Compare Smith, 593 F.3d at 284 (asserting that employees who work more
than forty hours per week are entitled to overtime pay under FLSA (citing 29
U.S.C. §§ 207, 213 (2006))), and id. at 284 (stating that white-collar exemptions
under FLSA should be narrowly construed against employer (citing Lawrence v.
City of Philadelphia, 527 F.3d 299, 310 (3d Cir. 2008))), and id. (explaining con-
trolling weight of regulations (citing Chevron U.S.A., Inc. v. Natural Res. Def.
Council, Inc., 467 U.S. 837, 843-44 (1984))), with Smith, 2008 WL 5427802, at *4-5
(discussing exemptions from FLSA overtime provisions).
112. Compare Smith, 593 F.3d at 284 (limiting focus to AEE), with Smith, 2008
WL 5427802, at *4-13 (analyzing Smith's role as PSR under both OSEE and AEE).
113. See Smith, 593 F.3d at 285 (relying heavily on Smith's deposition testi-
mony, which emphasized "the independent and managerial qualities that her posi-
tion required," to reach conclusion that she satisfied AEE); id. (drawing
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Interestingly, the Third Circuit asserted its holding first; then, the
Third Circuit backtracked to explain how the court arrived at its decision
in spite of Martin. 1 4 The Third Circuit agreed with the district court that
its decision in Martin predated the 2004 revisions to the regulations and,
therefore, warranted a departure from prior circuit precedent and a need
to look elsewhere for guidance." 5 Although the Third Circuit made a
fleeting reference to the Cote v. Burroughs Wellcome Co."' decision, the
court's decision ultimately rested heavily on Smith's deposition testimony
and the specific facts of the case." 7
IV. A "SECOND" OPINION
The Third Circuit's holding in Smith marked a paramount decision by
an appellate court regarding the exemption status of PSRs." 8 The court,
however, added a qualifying footnote, which recognized the possibility of
achieving a different result given different facts.1 19 Although the Third
Circuit forfeited the opportunity to firmly establish the proper FLSA classi-
fication of PSRs, the court's decision in Smith remains instructive, espe-
cially regarding the AEE analysis. 120
comparison between Smith's role as PSR and marketing representatives in Reich,
who satisfied AEE because they "dealt with licensed independent insurance agents
who, in turn, dealt with purchasers of insurance products" (citing Reich v. John
Alden Life Ins. Co., 126 F.3d 1, 3-5, 12 (1st Cir. 1997))). Compare id. (distinguish-
ing between Smith's role and PSR's role in Reich), with Smith, 2008 WL 5427802, at
*10 (relating Smith's role as "an educator and promoter" as similar to that of mar-
keting representatives in Reich).
114. See Smith 593 F.3d at 285-86 (affirming district court's judgment and ac-
knowledging that Third Circuit did "not overlook[ ]" its decision in Martin); id. at
286 (explaining that Third Circuit determined that Martin was "distinguishable on
the facts" and, therefore, irrelevant).
115. See id. at 286 (affirming district court's decision that "changes in the Sec-
retary's regulations since [Martin] make that case inapplicable here" (citing Smith,
2008 WL 5427802, at *8-9)).
116. 558 F. Supp. 883 (E.D. Pa. 1982)
117. See Smith 593 F.3d at at 285 (asserting that "medical 'detailer' "in Cote
qualified for AEE "even though description of employee's duties was more parsi-
monious than Smith's description of her duties" (citing Cote, 558 F. Supp. at 886-
87)); id. at 282-85 (believing Smith's deposition testimony to be accurate and re-
fusing to disregard it as "mere puffery").
118. See id. at 285-86 (distinguishing past precedent as irrelevant and finding
PSRs exempt from overtime pay); Robert Wolff, Third Circuit Finds Pharmaceutical
Sales Reps Exempt, HEALTHCARE EMP'T COUNSEL (Mar. 2, 2002), http://healthcare
employmentcounsel.com/class-actions/wage-and-hour-class-collective-actions/mis-
classification/third-circuit-finds-pharmaceutical-sales-representatives-exempt-1 /
(discussing Third Circuit's decision in Smith as "first federal appellate court deci-
sion to address the exemption status of [PSRs]").
119. See Smith, 593 F.3d at 283 n.1 (recognizing that "based on different facts,
courts, including this Court, considering similar issues involving sales representa-
tives for other pharmaceutical companies, or perhaps even forJ &J, might reach a
different result").
120. See id. (allowing for possibility of reaching alternate result).
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A. The Second Circuit's Misdiagnosis
Because any subsequent case involving the exemption status of PSRs
would arguably possess similar facts, the Third Circuit's wavering stance
effectively opened the door for a future circuit split. 12 1 Unsurprisingly,
the Second Circuit took advantage of this opportunity and assumed a rival
position in Novartis, ruling that the PSRs did not satisfy either the OSEE or
the AEE.122 The DOL, however, likely forced the Second Circuit's hand
by submitting an unexpected amicus brief in support of the PSRs. 123
Despite the response brief submitted by the Chamber of Commerce
that contested the DOL's views and claimed authority, the Second Circuit
was unwilling to challenge the status quo as the Third Circuit did in
Smith.124 Setting a new standard, the Third Circuit in Smith recognized
that the realities of the pharmaceutical industry and the impact of the
2004 revisions to the regulations could not be reconciled with past prece-
dent.125 The Second Circuit in Novartis, however, mistakenly assumed
that the DOL's amicus brief merited the same controlling weight histori-
cally afforded to other forms of the DOL's interpretive guidance. 12 6
121. See id. (acknowledging that decision was highly fact-sensitive and that
facts will vary from case to case).
122. See In re Novartis Wage and Hour Litig., 611 F.3d 141, 149 (2d. Cir. 2010)
(finding DOL's amicus brief was entitled to "controlling deference" and, there-
fore, concluding that PSRs were not exempt from overtime pay under either OSEE
or AEE), cert. denied, 131 S. Ct. 1568 (2011). Unlike the Third Circuit in Smith, the
Second Circuit in Novartis vacated the district court's judgment, which held that
PSRs were exempt under both the OSEE and AEE. Compare id. (vacating district
court's decision, which held that PSRs qualified for both OSEE and AEE), with
Smith, 593 F.3d at 286 (affirming district court's holding, which held that PSRs
were exempt from overtime pay under AEE).
123. See Novartis, 611 F.3d at 143-44 (discussing how Secretary of Labor sub-
mitted amicus brief in support of PSRs arguing that they were not exempt from
overtime pay under FLSA); id. at 149 (asserting that DOL's amicus brief was "enti-
tled to 'controlling' deference" and, therefore, determining that PSRs were not
exempt under either OSEE or AEE (citing Auer v. Robbins, 519 U.S. 452, 461
(1997))).
124. See id. at 149 (recognizing that Chamber of Commerce submitted amicus
brief in support of Novartis, which argued that DOL's amicus brief "merely par-
rot[ed]" regulations and, therefore, did not provide interpretive guidance); see also
Brief of the Chamber of Commerce of the United States of America as Amicus
Curiae in Support of Petitioner, Novartis Pharm. Corp. v. Lopes, 131 S. Ct. 1568
(2011) (No. 10-460), 2010 WL 4494106 (arguing that DOL's amicus brief should
not be accorded controlling deference and that PSRs should be exempt from over-
time pay).
125. For a further discussion of why the Third Circuit's decision in Smith war-
ranted a departure from the prior decision that was on point, see supra notes 114-
15 and accompanying text.
126. See Novartis, 611 F.3d at 149 (discussing DOL's ability to "define and de-
limit the terms used in the statute," which includes regulations and interpretations
of those regulations); id. at 153 (explaining that DOL's amicus brief was "entitled
to 'controlling' deference" because its "interpretations [were not] 'plainly errone-
ous or inconsistent with the regulation[s]"' (quoting Auer, 519 U.S. at 461) (inter-
nal quotation marks omitted)).
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While worthy of some deference, an amicus brief does not have the force
or effect of law, particularly when it is "inconsistent with the statutory lan-
guage and [the DOL's] prior pronouncements."' 2 7
Although the Third Circuit arrived at its decision in Smith without
confronting a corresponding DOL amicus brief, the court's analysis more
accurately captures the reality that most courts addressing this issue will
face: highly fact-sensitive cases that do not square with case law on
point.12 8 Further, the DOL's interpretive guidance is currently conflict-
ing; the DOL's recently terminated practice of issuing opinion letters pre-
cludes the possibility of formally alleviating any existing confusion. 129
Moreover, recent decisions involving the impact of DOL amicus briefs on
the exemption status of PSRs reveal the following: (1) the DOL will not
submit an amicus brief for every case and (2) even if the DOL submits an
amicus brief, courts will not interpret it as a substitute for an opinion let-
ter.1 30 Courts, therefore, should follow the Third Circuit's decision in
Smith, which places the onus on courts to consider all relevant factors and
transcend normative conventions. 13 1
127. See Christopher v. SmithKline Beecham Corp., No. CV-08-1498-PHX-
FJM, 2010 WL 396300, at *2 (D. Ariz. Feb. 1, 2010) (refusing to reconsider exemp-
tion status of PSR at issue in light of DOL's amicus brief that was submitted in
Novartis, and reasoning that DOL's amicus brief lacked authority and contradicted
prior interpretive guidance), affd, 635 F.3d 383 (9th Cir. 2011), cert. granted, No.
11-204, 2011 WL 3608968 (U.S. 2011). Because amicus briefs function similarly to
opinion letters, they should be accorded the same weight. See Gregory v. First Title
of Am., Inc., 555 F.3d 1300, 1302 (11th Cir. 2009) ("Agency opinion letters 'do not
warrant Chevron-style deference.' They are, however, 'entitled to respect under
Skidmore v. Swift & Co., 323 U.S. 134 (1944), but only to the extent that those
interpretations have the power to persuade."' (quoting Christensen v. Harris
Cnty., 529 U.S. 576, 587 (2000))).
128. See generally Smith v. Johnson & Johnson, 593 F.3d 280 (3d Cir. 2010)
(relying heavily on facts to find PSR at issue exempt from overtime pay). But see
S.D. Tex.: Upon Reconsideration, Pharmaceutical Reps Nonexempt; Court Elects to Adopt
Second Circuit's Reasoning, OVERTIME L. BLOC (Oct. 6, 2010, 10:46 AM), http://flsa
overtimelaw.com/2010/10/06/s-d-tex-upon-reconsideration-pharmaceutical-reps-
nonexempt-court-elects-to-adopt-second-circuits-reasoning/ (arguing that Third
Circuit's decision in Smith did not "consider[ ] impact of the DOL's amicus brief
on [its] decision [ ]" and, therefore, does "not provide a reasoned counterweight").
129. For a further discussion of the DOL's former practice of issuing fact-
specific opinion letters, see supra notes 62-63 and accompanying text.
130. See Schaefer-LaRose v. Eli Lilly & Co., No. 1:07-cv-1133-SEB-TAB, 2010
WL 3892464, at *1-2 (S.D. Ind. Sept. 29, 2010) (declining to revisit plaintiffs claim
in light of recent holding in Novartis, reasoning that their "decision cannot be a
swinging pendulum, vacillating back and forth as each new ruling addressing this
question is handed down by some court or another across the nation"); Christopher,
2010 WL 396300, at *1 (refusing to reconsider PSR's claim and reasoning that
DOL's amicus brief in Novartis was not entitled to degree of authority that Second
Circuit afforded it).
131. See Smith, 593 F.3d at 285-86 (recognizing that PSRs were exempt from
overtime pay by distinguishing current case from case law on point); id. at 283 n.1
(recognizing highly fact-sensitive nature of cases addressing exemption status of
PSRs).
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B. Will Courts Correct Novartis's Diagnostic Error?
Recent district court decisions indicate a trend toward the common
sense rationale that the Third Circuit encouraged in Smith.1 32 This, how-
ever, is not surprising considering the majority of lower courts followed
the district court's lead in Smith to find PSRs exempt from overtime
pay.1 33 Although PSRs have challenged these judgments in light of the
DOL's amicus brief submitted in Novartis, most courts have resisted the
opportunity to use the Second Circuit's contradictory decision to smudge
the Third Circuit's stamp of approval.13 4
Nonetheless, the DOL refuses to concede the issue; the DOL submit-
ted another amicus brief in support of PSRs for a case before the Ninth
Circuit.' 3 5 Although two recent decisions in the Second and Third Cir-
cuits reaffirmed the respective holdings in Novartis and Smith, the DOL did
132. See Christopher, 2010 WL 396300, at *2 (rejecting "absurdity" of DOL's
refusal to consider reality of pharmaceutical industry and goals of FLSA); Baum v.
AstraZeneca LP, 605 F. Supp. 2d 669, 687 (W.D. Pa. 2009) (emphasizing impor-
tance of common sense approach because "society is better off when a duck, walk-
ing and talking so, can simply be treated as one"), affd, 372 F. App'x 246 (3d Cir.
2010), cert. denied, 131 S. Ct. 332 (2010).
133. SeeJackson v. Alpharma, Inc., No. 07-3259, 2010 WL 2869530, at *3-5
(D.N.J. July 19, 2010) (finding PSRs exempt under AEE); Christopher v.
SmithKline Beecham Corp., No. CV-081498-PHX-FJM, 2009 WL 4051075, at *3-5
(D. Ariz. Nov. 20, 2009) (finding PSRs qualify for OSEE), aff'd, 635 F.3d 383 (9th
Cir. 2011), cert. granted, No. 11-204, 2011 WL 3608968 (U.S. 2011); Schaefer-La-
Rose v. Eli Lilly & Co., 663 F. Supp. 2d 674, 700 (S.D. Ind. 2009) (finding PSR
exempt under both AEE and OSEE); Harris v. Auxilium Pharm., Inc., 664 F. Supp.
2d 711, 733-42 (S.D. Tex. 2009) (same), vacated in part, 2010 WL 3817150 (S.D.
Tex. Sept. 28, 2010); Baum, 605 F. Supp. 2d at 675-87 (same); Delgado v. Ortho-
McNeil, Inc., No. SACV 07-00263-CJC(MLGx), 2009 WL 2781525, at *5 (C.D. Cal.
Feb. 6, 2009) (finding PSR exempt under OSEE); Yacoubian v. Ortho-McNeil
Pharm., Inc., No. SACV 07-00127-CJC(MLGx), 2009 WL 3326632, at *5 (C.D. Cal.
Feb. 6, 2009) (same). But seejirak v. Abbott Labs., Inc., 716 F. Supp. 2d 740, 749-
50 (N.D. Ill. 2010) (finding PSRs do not quality for OSEE or AEE); Kuzinski v.
Schering Corp., 604 F. Supp. 2d 385, 402-03 (D. Conn. 2009) (finding that PSRs
do not quality for OSEE), aff'd, 384 F. App'x 17 (2d Cir. 2010), cert. denied, 131 S.
Ct. 1567 (2011).
134. For a further discussion of the district court decisions in Schaefer-LaRose
and Christopher that declined to revisit claims of PSRs in light of amicus brief that
DOL submitted in Novartis, see supra note 130 and accompanying text, and Jackson,
2010 WL 2869530, at *5 (finding it unnecessary to address Second Circuit's deci-
sion in Novartis). But see Harris, 2010 WL 3817150, at *2-3 (reconsidering summary
judgment against PSRs in light of DOL's Novartis amicus brief).
135. See Christopher 635 F.3d at 391-95 (reconsidering whether DOL's views
regarding PSRs' exemption from overtime pay should be entitled to deference
under Chevron or Auer); Christopher Brief, supra note 60 (arguing that PSRs should
not be exempt from overtime pay); Sales Reps Not Exempt Salespeople, DOL Argues,
FLSA EMP. EXEMPTION HANDBOOK NEWSL., Oct. 2010, at 8 (discussing how DOL
filed "recent friend-of-the-court brief' and "urge [d] the 9th U.S. Circuit Court of
Appeals to reverse . . . district court's ruling" in Christopher, which held that PSRs
were exempt under OSEE).
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not submit an amicus brief in either of these cases. 13 6 The DOL, however,
recognized that the Ninth Circuit's case would likely exacerbate the ex-
isting circuit split, rather than simply serving as a tie-breaking decision.1 3 7
Specifically, the DOL feared that the Ninth Circuit would affirm the dis-
trict court's decision, which held that the PSRs at issue were exempt under
the OSEE.13 8 Additionally, the DOL feared that the Ninth Circuit would
adopt the district court's rationale, which reasoned that the DOL's amicus
brief in Novartis was not entitled to controlling deference.1 3 9 As a result,
the DOL strategically involved itself in the Ninth Circuit's case, attempting
to browbeat the court into finding favorably for the PSRs.14 0
Although the DOL's attempt was unsuccessful, its fears were not un-
founded; the Ninth Circuit aligned itself with the Third Circuit's decision
in Smith and maintained that PSRs were exempt from overtime pay under
the FLSA.14 1 Like the Third Circuit, the Ninth Circuit recognized that
finding otherwise would have contradicted "the statutory language and its
prior pronouncements" and "defied common sense."1 4 2 Nevertheless, the
136. Compare Kuzinski, 384 F. App'x at 18-19 (affirming Second Circuit's deci-
sion in Novartis and holding that PSRs were not exempt from overtime pay), with
Baum, 372 F. App'x at 249-50 (affirming Third Circuit's decision in Smith and de-
termining that PSRs were exempt under AEE).
137. See generally In re Novartis Wage and Hour Litig., 611 F.3d 141 (2d. Cir.
2010) (finding PSRs were not exempt from overtime under either OSEE or AEE),
cert. denied, 131 S. Ct. 1568 (2011); Smith v. Johnson &Johnson, 593 F.3d 280 (3d
Cir. 2010) (holding that PSRs were exempt under AEE but not addressing OSEE).
If the Ninth Circuit in Christopher were to affirm the district court's holding, its
judgment would not directly align with either the Second or Third Circuits' deci-
sions. See generally Christopher, 2009 WL 4051075 (determining that PSRs were ex-
empt under OSEE but not considering whether they were also exempt under
AEE).
138. See Christopher, 2009 WL 4051075, at *5 (declining to "adopt a hyper-
technical construction of the regulations that runs counter to the purpose of the
[FLSA]" and holding that PSRs "fit within the terms and spirit" of OSEE).
139. See Christopher v. SmithKline Beecham Corp., No. CV-08-1498-PHX-
FJM, 2010 WL 396300, at *1 (D. Ariz. Feb. 1, 2010) (disagreeing that DOL's amicus
brief in Novartis was entitled to controlling deference because it was not subject to
notice-and-comment procedures required by Administrative Procedure Act), aff'd,
635 F.3d 383, cert. granted, No. 11-204, 2011 WL 3608968 (U.S. 2011).
140. For a further discussion of how the DOL submitted an amicus brief in
Christopher to persuade the Ninth Circuit to vacate the district court's decision, see
supra note 135 and accompanying text. The DOL likely believed that its amicus
brief would be treated with controlling weight as it was in Novartis. For a further
discussion of how the Second Circuit in Novartis accorded the DOL's amicus brief
with deferential authority, see supra note 124 and accompanying text.
141. See Christopher, 635 F.3d 383 (refusing to accord DOL's amicus brief with
controlling deference and finding that PSRs were exempt from overtime pay). For
a further discussion of the Third Circuit's approach in Smith, see supra notes 110-
17, 126, 129, 132, and accompanying text.
142. Christopher, 635 F.3d at 389 (internal quotation marks omitted); see id. at
395-401 (explaining court's "common sense understanding of why PSRs make
sales"); id. at 401 (affirming district court's decision); Christopher, 2010 WL 396300,
at *2 (discussing illogicality of DOL's interpretation regarding PSRs, emphasizing
that role of PSRs must be considered with respect to pharmaceutical industry be-
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Ninth Circuit should be wary that a previously nonexistent player-the
Obama Administration-may second-guess its fact-based analysis.' 43
C. Will an Intervening Third Party Affect Prognosis?
Although the majority of courts addressing the exemption status of
PSRs have returned verdicts for employers, the Obama Administration re-
cently announced that it set aside $25 million to combat employee misclas-
sification.1 4 4 As a result, courts and employers should be prepared to face
increased scrutiny regarding the exemption status of PSRs.141 If courts do
not follow the Third Circuit's decision in Smith, pharmaceutical compa-
nies could be subject to the short-term "imposition of hundreds of mil-
lions of dollars in back pay liability for employers in the industry." 146 In
the long-term, however, failure to adhere to the Third Circuit's decision in
Smith "could . . . require a fundamental restructuring of the manner and
means by which pharmaceutical companies conduct their sales activities in
the U.S." 1 4 7 The exemption status of PSRs, therefore, may eventually war-
rant a decision by the Supreme Court, particularly as the circuit split deep-
ens and the Obama Administration becomes involved.' 4 8 In the interim,
cause "[a]ny other construction ignores reality and defeats the spirit and purpose"
of OSEE).
143. See Steven Greenhouse, U.S. Cracks Down on 'Contractors' as a Tax Dodge,
N.Y. TIMES, Feb. 18, 2010, at Al, available at http://www.nytimes.com/2010/02/
18/business/18workers.html?pagewanted=1&_r=1&adxnnl=1&adxnnlx=12978864
51-0XZFV%20M%2OYxQrHwNn6GZk%20Q (discussing Obama Administration as
undertaking unprecedented "crackdown" on employee misclassification by ex-
panding "enforcement personnel" and auditing employers).
144. See Budget Summary, in U.S. DEP'T OF LABOR, FY 2011 DEPARTMENT OF
LABOR BUDGET IN BRIEF 1, 1 (2010), available at http://www.dol.gov/dol/budget/
2011/PDF/bib.pdf (discussing DOL's increased 2011 budget, which is attributed
to "a joint Labor-Treasury initiative to strengthen and coordinate Federal and
State efforts to enforce statutory prohibitions, identify, and deter misclassifica-
tion"); Evan Spelfogel, President Obama Backs Department of Labor Misclassification
Fight, WAGE & HOUR DEFENSE BLOC (Feb. 11, 2010), http://www.wagehourblog.
com/2010/02/articles/dol-enforcement/president-obama-backs-department-of-la-
bor-misclassification-fight/ (stating that purpose of President Obama increasing
DOL's budget was to help DOL battle employee misclassification, especially re-
garding employees who do not meet requirements of white-collar exemptions).
145. See Spelfogel, supra note 144 (stating that budget will be used to "iden-
tify[] and litigat[e] against employers" that have miscategorized workers as ex-
empt under FLSA); id. (discussing proliferation of "[i]ndividual, class[,] and
collective actions" as consequences of employee misclassification).
146. Blackburn, supra note 8, at 159 (predicting immediate ramifications on
individual pharmaceutical companies if courts follow Second Circuit's decision in
Novartis and return verdicts for PSRs).
147. Id. (predicting long-term effects on entire pharmaceutical industry if
courts follow Second Circuit's decision in Novartis and return verdicts for PSRs).
148. See id. (determining possible need for "definitive answer" from United
States Supreme Court because of number of cases addressing issue). For a further
discussion of the circuit split that resulted from the Second Circuit's decision in
Novartis, see supra notes 121-31 and accompanying text. For a further discussion of
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however, practitioners and employers should use the Third Circuit's deci-
sion in Smith as a guide."'
V. REMEDIES TO USE WHILE AWAITING A CURE
Because of the increased pressures from the DOL and the Obama
Administration, employers and practitioners can expect an influx of mis-
classification lawsuits filed by employees.15 0 Although the Third Circuit's
decision in Smith was favorable for employers, all parties should take note
of the factors that influenced its decision. 15 1 Additionally, the Third Cir-
cuit's analysis in Smith is instructive outside the limited context of PSRs
because the evolving nature of the modern workforce increases the likeli-
hood that employees will perform non-traditional roles similar to PSRs. 152
First, Smith demonstrates that employers must carefully delineate and
assign an employee's duties, recognizing that an employee's title alone is
not dispositive. 153 Second, Smith warns potential plaintiffs that cases are
highly fact-sensitive and, therefore, their deposition testimony may be out-
come-determinative.1 54 As a result, litigators should use the plaintiffs
the Obama Administration's initiative regarding employee misclassification, see
supra notes 143-45 and accompanying text.
149. See generally Smith v. Johnson & Johnson, 593 F.3d 280 (3d Cir. 2010)
(addressing exemption status of PSRs and analyzing issue in light of realities of
industry, spirit of white-collar exemptions, and specific facts of case).
150. See U.S. DEPT OF LABOR, STRATEGIC PLAN FIsCAL YEARS 2011-2016, at 31-
32 (2010), available at http://www.dol.gov/_sec/stratplan/StrategicPlan.pdf (de-
lineating DOL's aggressive proposals to combat employee misclassification). For a
further discussion of how the Obama Administration's concentrated efforts will
likely result in uptick in wage and hour claims filed against employers, see supra
notes 144-46 and accompanying text.
151. See generally Smith, 593 F.3d 280 (affirming district court's grant of sum-
mary judgment for employer and determining that PSRs were exempt from over-
time pay). For a further discussion of how the Third Circuit in Smith accounted for
factors that other courts have ignored when addressing exemption status of PSRs,
see supra notes 110-17, 125, and accompanying text.
152. See generally Gregory v. First Title of Am., Inc., 555 F.3d 1300 (11th Cir.
2009) (finding that "marketing director" for title insurance company qualified for
OSEE because employee focused her efforts on sales that would later be credited
to her); Rothe, supra note 20, at 711 (" [M]ore than twenty-five million Americans
currently work more than forty-nine hours each week-most of them white-collar
professionals.").
153. See 29 C.F.R. § 541.2 (2005) ("Ajob title alone is insufficient to establish
the exempt status of an employee."); Defining and Delimiting the Exemptions for
Executive, Administrative, Professional, Outside Sales and Computer Employees,
69 Fed. Reg. 22,122, 22,160, 22,163 (Apr. 23, 2004) (stressing that "an employee's
job duties, not job title, determine whether the exemption applies" and discussing
possibility that job titles "may not accurately reflectjob duties and actual perform-
ance" (emphasis added)); see also Smith, 593 F.3d at 283 (discussing how PSR's job
description "required [her] to plan and prioritize her responsibilities in a manner
that maximized business results").
154. See Smith, 593 F.3d at 283 (explaining that PSR's deposition testimony
was significant in determining facts of case); id. at 285 (asserting that court "ac-
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deposition testimony to their respective advantage. 15 5 Practitioners repre-
senting the plaintiff should prevent the employee from emphasizing the
importance of his or her position, warning the plaintiff that his or her
deposition cannot be retracted later.15 6 Conversely, practitioners repre-
senting the employer should exploit the employee's inflated self-impor-
tance and expose the plaintiffs attempts to re-characterize his or her
deposition testimony.15 7 Finally, Smith encourages courts to consider the
realities of the industry at issue and the modern work environment when
evaluating an employee's exemption status.' 5 8
cept[ed] Smith's deposition testimony as an accurate description of her position");
id. (concluding that PSR was exempt under AEE based on her testimony).
155. Compare Brief of Appellee/Cross-Appellant Johnson & Johnson, Smith,
593 F.3d 380 (Nos. 09-1223, 09-1292), 2009 WL 5635400 (arguing that opponent's
brief contradicted evidence, especially PSR's own deposition testimony that "con-
clusively establishe[d]" that she should be exempt from overtime pay), with Reply
Brief of Plaintiff-Appellant and Response Brief to the Cross Appeal, Smith, 593 F.3d
280 (Nos. 09-1223, 09-1292), 2009 WL 5635399 (arguing that PSR's deposition was
"a superficial characterization," which resulted from "selective and leading
questions").
156. See Smith, 593 F.3d at 285 (accepting Smith's deposition testimony as an
accurate description of her position); id. (discussing how employee "understood
the significance of her testimony in the context of this case"); id. at 285 n.3 (dis-
cussing how principle behind "the 'sham affidavit' doctrine" was applicable be-
cause court refused to accept contention by Smith's counsel, which argued that
court should disregard Smith's deposition as "puffery").
157. See id. at 285 (refusing to accept argument by PSR's counsel that em-
ployee's deposition testimony "overinflated her importance"); Reply Brief on
Cross-Appeal of Appellee/Cross-AppellantJohnson &Johnson, Smith, 593 F.3d 280
(Nos. 09-1223, 09-12921), 2009 WL 5635401 (discussing self-incriminating nature
of Smith's testimony, which emphasized characteristics required to meet
exemption).
158. See Smith, 593 F.3d at 282 (recognizing that realities of pharmaceutical
industry precluded PSR from directly selling prescription product to physician); id.
at 285-86 (evaluating role of PSR in context of pharmaceutical industry to deter-
mine that she was exempt from overtime pay under AEE).
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